(S)-(+)-二氢吲哚-2-甲醇 | 27640-33-1

• 物质功能分类: 有机原料 - 醇、酚、酚醇类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: (S)-(+)-二氢吲哚-2-甲醇
• 中文别名: (S)-(+)-2-吲哚啉甲醇；(S)-(+)-二氢吲哚-2-甲醇,98+；(S)-(+)-2-二氢吲哚甲醇；(S)-(+)-二氢吲哚-2-甲醇, 98+%
• 英文名称: (2S)-2,3-dihydro-1H-indole-2-ylmethanol
• 英文别名: (S)-indolin-2-ylmethanol；(S)-(-)-2-(hydroxymethyl)indoline；[(2S)-indolin-2-yl]methanol；(S)-(+)-2-Indolinemethanol；[(2S)-2,3-dihydro-1H-indol-2-yl]methanol
• CAS: 27640-33-1
• 化学式: C₉H₁₁NO
• 分子量: 149.192
• InChiKey: GRPOFAKYHPAXNP-QMMMGPOBSA-N

物化性质

• 熔点：
  64.5-69.5 °C(lit.)
• 比旋光度：
  +50～+54°(c=1, EtOH, 22℃)
• 沸点：
  309.1±11.0 °C(Predicted)
• 密度：
  1.120±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解。避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 安全说明：
  S26,S36
• WGK Germany：
  3
• 储存条件：
  保持贮藏器密封，并将其放入一个紧密封装的容器中。储存时，请确保放置在阴凉、干燥的地方。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (S)-(+)-2-Indolinemethanol
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: (S)-(+)-2-Indolinemethanol
CAS number: 27640-33-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H11NO
Molecular weight: 149.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-(+)-二氢吲哚-2-甲醇 在 吡啶 、 sodium tetrahydroborate 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 82.0h， 生成 (R)-N-(tert-butoxycarbonyl)-2-methylindoline
  参考文献：
  名称：

  [EN] FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS
  [FR] UTILISATION DE DÉRIVÉS THIAZOLOPYRIMIDINE FUSIONNÉS COMME INHIBITEURS DE MNSK

  摘要：

  本发明涉及公式I和H的化合物，或其药用盐或酯。该发明的进一步方面涉及药物组合物以及所述化合物在治疗未受控制的细胞生长、增殖和/或存活、不当的细胞免疫反应、不当的细胞炎症反应或神经退行性疾病，更好地说是tau病变疾病，甚至更好地说是阿尔茨海默病的治疗用途。

  公开号：

  WO2017085484A1
• 作为产物：
  描述：

  吲哚-2-甲酸乙酯 在 盐酸 、 4-二甲氨基吡啶 、 氢氧化钾 、 lithium aluminium tetrahydride 、 三乙胺 、 2-甲氧基乙胺 作用下， 以 乙醚 、 二氯甲烷 、 水 、 二甲基亚砜 为溶剂， 反应 6.17h， 生成 (S)-(+)-二氢吲哚-2-甲醇
  参考文献：
  名称：

  （巯基丙酰基）二氢吲哚-2-羧酸和相关化合物作为有效的血管紧张素转化酶抑制剂和降压药。

  摘要：

  合成了1-（3-巯基-2-甲基-1-氧丙基）二氢吲哚-2-羧酸（7b）及其相关化合物，以检测其抑制血管紧张素转化酶（ACE）和降低收缩压的能力自发性高血压大鼠（SHR）。前体1- [3-（苯甲硫基）-2-甲基-1-氧丙基]二氢吲哚-2-羧酸（6b）的所有四种可能的立体异构体均具有绝对立体化学特征。通过用2-甲氧基乙胺处理方便地除去前体的苯甲酰基以得到7b。苯甲酰基衍生物6的四个立体异构体中的三个以下列顺序显示了体外ACE抑制活性：6b（S，S）大于6b（S，R）大于6b（R，S）。具有R，R构型的立体异构体基本上是无活性的。用Et或OMe组取代吲哚核的C5处，仅引起抑制活性的微小变化。硫醇7b（S，S）是这项研究中合成的最具活性的ACE抑制剂，其体外效能是卡托普利的3倍。与卡托普利相比，效力的增强可能是由于7b（S，S）的疏水性增加，并表明在ACE的活性位点存在疏水口袋。在自发性高血压大鼠

  DOI：

  10.1021/jm00357a014
• 作为试剂：
  描述：

  1,1-dimethoxy-3-nitro-2-propene 、 丙醛 在 (S)-(+)-二氢吲哚-2-甲醇 作用下， 以 四氢呋喃 为溶剂， 反应 312.0h， 生成 4,4-dimethoxy-2-methyl-3-(nitromethyl)butanal 、 (2S,3S)-3-(dimethoxymethyl)-2-methyl-4-nitrobutyraldehyde 、 (2R,3R)-3-(dimethoxymethyl)-2-methyl-4-nitrobutyraldehyde
  参考文献：
  名称：

  高度官能化的多取代吡咯烷的有机催化对映选择性合成。

  摘要：

  已经详细研究了将不同的醛有机催化共轭加成到β-硝基丙烯醛二甲基乙缩醛中，以高收率和高立体选择性产生相应的高度官能化的硝基醛。这些转化是通过使用1：1比例的容易获得的起始原料以及催化剂负载量为10 mol％的市售催化剂来实现的。此外，已经设计了一种非常短而有效的方案，用于从获得的迈克尔加合物开始制备高度对映体富集的吡咯烷，其包含两个或三个连续的立体中心。通过Zn介导的硝基化学选择性还原硝基，然后进行分子内还原胺化，一步即可获得3,4-二取代的吡咯烷，

  DOI：

  10.1002/chem.200800788

文献信息

• FLAP MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20150259357A1

  公开（公告）日：2015-09-17

  The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R 1 , R 2 , R 3 , R 3 ′, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention

  本发明涉及式（I）的化合物，或其形式，其中环A，R1，R2，R3，R3'，L，W和V如本文所定义，可用作FLAP调节剂。该发明还涉及包含式（I）化合物的药物组合物。制备和使用式（I）化合物的方法也属于本发明的范围。
• [EN] POLYCYCLIC AMIDES AS CYTOTOXIC AGENTS<br/>[FR] AMIDES POLYCYCLIQUES SERVANT D'AGENTS CYTOTOXIQUES
  申请人：FEMTOGENIX LTD

  公开号：WO2020049286A1

  公开（公告）日：2020-03-12

  The invention relates to a compound of formula (I): or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers or mixtures thereof; wherein the fused ring moiety is a non-alkylating moiety; and wherein the compounds are useful as medicaments, in particular for use as a drug in an antibody-drug conjugate and in the treatment of a proliferative disease, a bacterial infection, a malarial infection and inflammation.

  该发明涉及公式(I)的化合物；或其药学上可接受的盐、溶剂合物、互变异构体、立体异构体或它们的混合物；其中融合环基团是非烷基化基团；这些化合物可用作药物，特别是用作抗体药物结合物中的药物，以及用于治疗增殖性疾病、细菌感染、疟疾感染和炎症。
• [EN] MODULATORS OF AMYLOID BETA.<br/>[FR] MODULATEURS DE LA PROTÉINE ?-AMYLOÏDE
  申请人：ASTRAZENECA AB

  公开号：WO2010053438A1

  公开（公告）日：2010-05-14

  The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and/or prevention of various diseases. In particular the invention relates to compounds, which inhibit the Aβ40 and Aβ42 production, increase the Aβ37 and Aβ38 production and maintain the Notch signaling and will be used for treatment and/or prevention of Aβ-related pathologies such as Alzheimer's disease, Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及式I的新化合物及其治疗上可接受的盐，它们的药物组合物，制造它们的方法以及它们作为治疗和/或预防各种疾病的治疗方法的使用。特别是，本发明涉及抑制Aβ40和Aβ42产生，增加Aβ37和Aβ38产生并维持Notch信号传导的化合物，并将用于治疗和/或预防与Aβ相关的病理，如阿尔茨海默病、唐氏综合症和β-淀粉样蛋白血管病，例如但不限于脑淀粉样血管病、遗传性脑出血、与认知障碍相关的疾病，例如但不限于MCI（“轻度认知障碍”）、阿尔茨海默病、记忆丧失、与阿尔茨海默病相关的注意力缺陷症状、与阿尔茨海默病或包括混合血管和退行性来源的痴呆在内的疾病相关的神经退行性变、早老性痴呆、老年性痴呆和与帕金森病、进行性核上瘫或皮层基底退行性变相关的痴呆。
• [EN] APOPTOSIS-INDUCING AGENTS<br/>[FR] AGENTS INDUISANT L'APOPTOSE
  申请人：SHANGHAI FOCHON PHARMACEUTICAL CO LTD

  公开号：WO2018192462A1

  公开（公告）日：2018-10-25

  Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

  提供了某些Bcl-2抑制剂，其药物组成物，以及其使用方法。
• 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
  申请人：Hutchinson H. John

  公开号：US20070105866A1

  公开（公告）日：2007-05-10

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本发明描述了调节5-脂氧合酶激活蛋白(FLAP)活性的化合物和含有该化合物的药物组合物。本发明还描述了单独使用和与其他化合物联合使用FLAP调节剂，用于治疗呼吸系统、心血管系统和其他白三烯依赖性或白三烯介导的状况或疾病。